Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of GSK3732394 in Healthy Participants
NCT03984812Phase 1Terminated
- Sponsor
- ViiV Healthcare
- Start
- Jun 2019
- Primary completion
- Mar 2020
- Modality
- Recombinant Proteins and Enzymes, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK3732394 in human immunodeficiency virus infection (HIV) (9 cohorts), sponsored by ViiV Healthcare. Primary endpoints: Number of Participants With Non-serious Adverse Event (SAEs) and SAEs, Number of Participants With Clinical Chemistry Parameters by Maximum Grade Increase Post-Baseline and 2 more. Started Jun 2019; status: terminated.
02
Drugs
GSK3732394
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03984812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03984812.